PLAT and brain ischemia: As we know, tissue plasminogen activator (t-PA) is the only US Food and Drug Administration (FDA) approved drug for acute stroke treatment, and its clinical use is limited by its narrow therapeutic time window (~4.5 h) and propensity to cause hemorrhagic transformations (HT) after cerebral ischemia [57].